Public Health Agency of Canada
Symbol of the Government of Canada

Publicly Funded Immunization Programs in Canada - Routine Schedule for Infants and Children including special programs and catch-up programs (as of March, 2015)

Information on immunization programs was collected by the Canadian Nurses Coalition on Immunization (CNCI). PHAC and the CNCI have worked together since July 2004 to develop this tool containing the latest provincial/territorial program information.

Routine Schedule for Infants and Children
Province or Territory DTaP-
IPV-Hib
DTaP-
IPV
Tdap or Tdap-IPV HB MMR Var MMR-Var Men-C Men-C-A CYW-135 Pneu-C-13 Inf HPV Rot
Legend:
DTaP:
Diphtheria, Tetanus, Acellular Pertussis
HB:
Hepatitis B
Hib:
Haemophilus Influenzae Type b
HPV:
Human Papillomavirus
Inf:
Influenza
IPV:
Inactivated Poliomyelitis
Men-C:
Meningococcal conjugate
MMR:
Measles, Mumps, Rubella
MMR-Var
Measles, Mumps, Rubella, and Varicella
Pneu-C-13
Pneumococcal conjugate 13 valent
Pneu-P-23
Pneumococcal polysaccharide 23 valent
Rot:
Rotavirus
Tdap:
Tetanus, Diptheria, Acelluar Pertussis
Var:
Varicella
HR:
Children at high risk only (Definitions of High Risk for Publicly-funded Vaccines by Province/Territory)
N:
None
Source: Canadian Nurses Coalition on Immunization, 2013
Recommended use:
  1. If meningococcal C conjugate vaccine is given to infants < 12 months of age, a booster dose should be given in the second year of life (from 12 to 23 months of age). The early adolescent dose may be given using either meningococcal C conjugate (Men-C) vaccine or quadrivalent conjugate meningococcal vaccine (Men-C-ACYW) depending on the burden of illness from serogroups A, Y and W135 and the age distribution of cases by serogroup in individual Provinces / territories. Updated Invasive Meningococcal Vaccine Conjugate Recommendations can be found at: Update on the Invasive Meningococcal Disease and Meningococcal Vaccine Conjugate Recommendations (PDF Document - 712 Kb - 40 pages)
  2. The HPV vaccine is recommended for females (HPV2 or HPV4) and males (HPV4) between 9 and 14 years of age.
    Update on the recommended Human Papillomavirus (HPV) vaccine immunization schedule
NACI recom-
mendation
2, 4, 6, 18 mths 4-6 yrs 14-16 yrs Infancy
(3 doses)
OR
Pre-teen/teen

(2-3 doses)
12 mths
AND
18 mths OR
4-6 yrs
OR
MMR-Var 2 doses
12-18 mths
AND
18 mths OR
4-6 yrs
OR
MMR-Var 2 doses
12 mths
AND
18 mths OR
4-6 yrs
Infancy (1-4 doses)Footnote1 AND Pre-teen (1 dose)Footnote1 Pre-teen (1 dose)Footnote1 2, 4, 6, 12-15 mths 6-59 mths
(1-2 doses)
9-14 yrs
(2 doses at 0, 6-12 mths)Footnote2
2, 4, 6 mths
BC 2, 4, 6 (DTaP-
HB-IPV-Hib),
18 mths
(DTaP-
IPV-Hib)
4-6 yrs Tdap
Gr. 9
2, 4, 6 mths (DTaP- HB-IPV-Hib) 12 mths 12 mths 4-6 yrs 2, (4 HR), 12 mths,
Gr. 6
N 2, 4, (6 HR), 12 mths 6-59 mths, HR > 5 yrs Females,
Gr. 6 (2 doses 6 mths apart)
2, 4 mths
AB 2, 4, 6, 18 mths 4-6 yrs Tdap
Gr. 9
Gr. 5 N N 12 mths, 4-6 yrs 4, 12 mths Grade 9
(1 dose)
2, 4, (6 HR), 12 mths ≥ 6 mths Gr. 5
Catch-up
Males
Gr. 9
2, 4 mths (starting June 01, 2015)
SK 2, 4, 6, 18 mths 4-6 yrs Tdap
Gr. 8
Gr. 6 N Catch-up Gr. 6 until Aug 2015 12, 18 mths 12 mths Gr. 6 2, 4, (6 HR), 12 mths ≥ 6 mths Females
Gr. 6
2, 4 mths
MB 2, 4, 6, 18 mths N Tdap-IPV
4-6 years,
Tdap 14-16 yrs
Gr. 4 (starting Sept 2017, 2 doses in Gr.6) N N 12 mths, 4-6 yrs 12 mths, Gr. 4 (moving to Gr.6 in Sept 2019) N 2, 4, (6 HR), 12 mths ≥ 6 mths Females
Gr. 6;
2, 4 mths
ON 2, 4, 6, 18 mths N Tdap-IPV 4-6 yrs, Tdap 14-16 yrs Gr. 7 12 mths 15 mths 4-6 yrs 12 mths Gr. 7 2, 4, (6 HR), 12 mths ≥6 mths Females
Gr. 8
Catch-up until Gr. 12
2, 4 mths
QC 2, 4, 18 (DTaP-
HB-IPV-Hib), 6 mths (DTaP-IPV-Hib)
N Tdap-IPV 4-6 yrs,
Tdap 3rd year of high school
2, 4, 18 (DTaP- HB-IPV-Hib), Gr. 4 12 mths N 18 mths 12 mths, 3rd year of high school; Catch-up < 18 yrs N 2, 4, (6 HR)12 mths 6-23 mths Females
Gr. 4; Catch-up Females < 18 yrs
2, 4 mths
NB 2, 4, 6, 18 mths   Tdap-IPV 4 yrs, Tdap
Gr. 7
0, 2, 6 mths N Catch-up One dose children born between 2000 and 2008, 2 doses children born in 2009 or later 12, 18 mths 12 mths Gr. 9 2, 4, 12 mths mths - 18 yrs Females
Gr. 7
N
NS 2, 4, 6, 18 mths N Tdap-IPV 4-6 yrs, Tdap
Gr. 7
Gr. 7 N N 12, 18 mths; Catch-up 4-6 yrs 12 mths, Gr. 7 N 2, 4, 12 mths ≥ 6 mths Females
Gr. 7
N
PE 2, 4, 6, 18 mths 4-6 yrs Tdap
Gr. 9
2, 4, 18 mths N N 12, 18 mths 12 mths Gr. 9 2, 4, (6 HR), 18 mths 6-59 mths Gr. 6 2, 4 mths
NL 2, 4, 6, 18 mths 4-6 yrs Tdap Gr. 9 Gr. 6 (2 doses, 4 months apart) N N 12, 18 mths 12 mths Gr. 4 2, 4, 12 mths ≥ 6 mths Females
Gr. 6
N
NT 2, 4, 6, 18 mths 4-6 yrs Tdap Gr. 9 0, 1, 6 mths; Catch-up > 5 yrs, Gr. 4 and Gr.9 Catch-up pre-kindergarten, Gr. 4 and Gr. 9 Catch-up <5 yrs, Gr. 4 and Gr.9 (students who have received only 1 dose prior) 12, 36 mths;
Catch-up Pre-kindergarden, ≤ 12 yrs (school)
2, 12 mths;
Catch-up <5 yrs, Gr. 4 and Gr. 9
Gr. 12 students who will be attending post- secondary education outside NT 2, 4, 6, 18 mths ≥ 6 mths Females Gr.4-6;
Catch-up Gr.9-12
2, 4 mths
YT 2, 4, 6 (DTaP- HB-IPV-Hib), 18 mths (DTaP-IPV-Hib)   Tdap-IPV 4-6 yrs, Tdap Gr. 9 2, 4, 6 mths (DTaP- HB-IPV-Hib); Catch-up ≤19 yrs 12 mths, 4-6 yrs 12 mths,
4-6 yrs
N 2, 12 mths; Gr. 6, post-secondary students not previously immunized N 2, 4, (6 HR), 12 mths
(3 doses) (4 dose series for high risk)
1 dose for HIV+ ≥60 months of age not previously immunized)
≥ 6 mths Females
Gr. 6 (2 doses)
2, 4 mths
NU 2, 4, 6, 18 mths 4-6 yrs Tdap
Gr. 9
(14-16 yrs)
0, 1, 9 mths 12, 18 mths; Catch-up
Gr. 12
15 mths N 12 mths;
Catch-up Gr. 9 (14-16 yrs)
N 2, 4, 6, 15 mths, plus Pneu-P-23 (1 dose) 2-3 yrs Universal ≥ 6 mths Females Gr. 6
(≥ 9 yrs)
N